Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL

Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL

Abstract Background This study was performed to examine the usefulness of combined androgen blockade (CAB) therapy with a gonadotropin-releasing hormone (GnRH) antagonist (CAB-antagonist therapy), instead of CAB therapy with GnRH agonist (CAB-agonist therapy) against very high-risk prostate cancer (...

Full description

Bibliographic Details
Main Authors: Takeshi Kashiwabara, Sayo Suda
Format: Article
Language:English
Published: BMC 2018-05-01
Series:BMC Cancer
Subjects:
Bone metastasis
Combined androgen blockade
Gonadotropin-releasing hormone receptor antagonist
Prostate cancer
Online Access:http://link.springer.com/article/10.1186/s12885-018-4541-0

Internet

http://link.springer.com/article/10.1186/s12885-018-4541-0

Similar Items